NeuHyll

NeuHyll is an early-stage biotechnology company focused on developing innovative treatments for chronic neuropathic pain and neurodegenerative conditions. The company utilizes a proprietary platform that leverages modified hyaluronic acid (hyaluronan) to create localized, sustained-release delivery systems for neuro-active compounds. By targeting the microenvironment of damaged nerves and the central nervous system, NeuHyll aims to provide non-opioid alternatives for pain management and promote neural regeneration. Their research is centered on optimizing the interaction between therapeutic ligands and neural receptors to improve functional recovery in patients with spinal cord injuries and cognitive decline.